Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial.
Vera BrilRobert D M HaddenThomas H BrannaganMichal BarElisabeth ChroniKonrad RejdakAlberto RiveroHenning AndersenNorman LatovTodd LevineMamatha PasnoorSabrina SacconiNizar SouayahColin Anderson-SmitsKim DuffErin GrecoShabbir HasanZhaoyang LiLeman YelHakan AyPublished in: Journal of the peripheral nervous system : JPNS (2023)
fSCIG 10% more effectively prevented CIDP relapse than placebo, supporting its potential use as maintenance CIDP treatment. This article is protected by copyright. All rights reserved.